Schaper Benz & Wise Investment Counsel’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $12.4M | Buy |
19,928
+79
| +0.4% | +$53.8K | 0.83% | 45 |
|
|
2026
Q1 | $15.3M | Sell |
19,849
-675
| -3% | -$517K | 1.17% | 32 |
|
|
2025
Q4 | $15.8M | Sell |
20,524
-1,204
| -6% | -$818K | 1.14% | 33 |
|
|
2025
Q3 | $12.2M | Sell |
21,728
-629
| -3% | -$356K | 0.91% | 45 |
|
|
2025
Q2 | $11.7M | Buy |
22,357
+2,259
| +11% | +$1.26M | 0.9% | 45 |
|
|
2025
Q1 | $12.7M | Buy |
20,098
+764
| +4% | +$525K | 1.03% | 36 |
|
|
2024
Q4 | $13.8M | Buy |
19,334
+1,220
| +7% | +$1.02M | 1.11% | 37 |
|
|
2024
Q3 | $19M | Buy |
18,114
+189
| +1% | +$210K | 1.52% | 25 |
|
|
2024
Q2 | $18.8M | Sell |
17,925
-85
| -0.5% | -$82.4K | 1.63% | 22 |
|
|
2024
Q1 | $17.3M | Buy |
18,010
+87
| +0.5% | +$82.7K | 1.45% | 29 |
|
|
2023
Q4 | $15.7M | Sell |
17,923
-26
| -0.1% | -$21.4K | 1.42% | 30 |
|
|
2023
Q3 | $14.8M | Sell |
17,949
-65
| -0.4% | -$51.1K | 1.46% | 26 |
|
|
2023
Q2 | $12.9M | Buy |
18,014
+601
| +3% | +$463K | 1.24% | 34 |
|
|
2023
Q1 | $14.3M | Sell |
17,413
-181
| -1% | -$137K | 1.45% | 30 |
|
|
2022
Q4 | $12.7M | Sell |
17,594
-1,167
| -6% | -$861K | 1.35% | 31 |
|
|
2022
Q3 | $12.9M | Sell |
18,761
-1,052
| -5% | -$662K | 1.5% | 27 |
|
|
2022
Q2 | $11.7M | Sell |
19,813
-898
| -4% | -$584K | 1.21% | 38 |
|
|
2022
Q1 | $14.5M | Sell |
20,711
-456
| -2% | -$288K | 1.25% | 36 |
|
|
2021
Q4 | $13.4M | Buy |
21,167
+304
| +1% | +$187K | 1.07% | 43 |
|
|
2021
Q3 | $12.6M | Buy |
20,863
+198
| +1% | +$123K | 1.13% | 40 |
|
|
2021
Q2 | $11.5M | Buy |
20,665
+303
| +1% | +$154K | 1.04% | 42 |
|
|
2021
Q1 | $9.63M | Buy |
20,362
+2,036
| +11% | +$991K | 0.94% | 44 |
|
|
2020
Q4 | $8.85M | Sell |
18,326
-105
| -0.6% | -$56.7K | 0.92% | 45 |
|
|
2020
Q3 | $10.3M | Buy |
18,431
+92
| +0.5% | +$55.8K | 1.2% | 38 |
|
|
2020
Q2 | $11.4M | Sell |
18,339
-410
| -2% | -$233K | 1.42% | 29 |
|
|
2020
Q1 | $9.15M | Buy |
18,749
+96
| +0.5% | +$39.6K | 1.33% | 34 |
|
|
2019
Q4 | $7M | Sell |
18,653
-867
| -4% | -$292K | 0.82% | 49 |
|
|
2019
Q3 | $5.42M | Buy |
19,520
+672
| +4% | +$199K | 0.68% | 53 |
|
|
2019
Q2 | $5.9M | Buy |
18,848
+2,022
| +12% | +$673K | 0.75% | 49 |
|
|
2019
Q1 | $6.91M | Buy |
16,826
+216
| +1% | +$88.9K | 0.9% | 47 |
|
|
2018
Q4 | $6.2M | Buy |
16,610
+175
| +1% | +$64.1K | 0.93% | 46 |
|
|
2018
Q3 | $6.64M | Sell |
16,435
-425
| -3% | -$162K | 0.89% | 47 |
|
|
2018
Q2 | $5.82M | Buy |
16,860
+1,493
| +10% | +$467K | 0.83% | 49 |
|
|
2018
Q1 | $5.29M | Buy |
15,367
+2,369
| +18% | +$824K | 0.78% | 49 |
|
|
2017
Q4 | $4.89M | Buy |
12,998
+2,794
| +27% | +$1.13M | 0.71% | 53 |
|
|
2017
Q3 | $4.56M | Buy |
10,204
+1,182
| +13% | +$562K | 0.71% | 53 |
|
|
2017
Q2 | $4.43M | Buy |
9,022
+70
| +0.8% | +$30.6K | 0.71% | 54 |
|
|
2017
Q1 | $3.47M | Buy |
8,952
+1,761
| +24% | +$653K | 0.59% | 56 |
|
|
2016
Q4 | $2.64M | Buy |
7,191
+1,799
| +33% | +$684K | 0.47% | 63 |
|
|
2016
Q3 | $2.17M | Buy |
5,392
+2,007
| +59% | +$805K | 0.38% | 63 |
|
|
2016
Q2 | $1.18M | Buy |
+3,385
| New | +$1.3M | 0.21% | 71 |
|
|
2016
Q1 | – | Sell |
-415
| Closed | -$225K | – | 100 |
|
|
2015
Q4 | $225K | Buy |
+415
| New | +$225K | 0.04% | 93 |
|
Other funds holding REGN
MCI
Schaper Benz & Wise Investment Counsel's REGN Position: Q2 2026 in Review
Schaper Benz & Wise Investment Counsel increased its Regeneron Pharmaceuticals (REGN) stake by 0.4% in Q2 2026, buying an estimated $53.8K and bringing the position to 19,928 shares worth $12.4M. The position accounts for 0.83% of the portfolio, ranked #45.
Schaper Benz & Wise Investment Counsel first reported a position in REGN in Q4 2015 and has held it in 42 quarters since. The position peaked at $19M in Q3 2024. 472 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Schaper Benz & Wise Investment Counsel held 19,928 shares of Regeneron Pharmaceuticals worth $12.4M as of Q2 2026.
- Schaper Benz & Wise Investment Counsel bought 79 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $53.8K.
- Regeneron Pharmaceuticals made up 0.83% of Schaper Benz & Wise Investment Counsel's portfolio in Q2 2026, its #45 holding.
- Schaper Benz & Wise Investment Counsel first reported a position in Regeneron Pharmaceuticals in Q4 2015 and has held it in 42 quarters since.
- Schaper Benz & Wise Investment Counsel's Regeneron Pharmaceuticals position peaked at $19M in Q3 2024.
- 472 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Schaper Benz & Wise Investment Counsel's 13F filing for Q2 2026, filed 21 Jul 2026.